Revvity Inc (NYSE:RVTY) Q3 2025 Earnings: EPS Beats Estimates, Revenue Falls Short

Revvity Inc (NYSE:RVTY) has announced its financial results for the third quarter of 2025, presenting a performance that narrowly surpassed analyst expectations on profitability while delivering revenue largely in line with forecasts. The company's latest earnings report reveals a business navigating a complex operational environment, achieving modest top-line growth amid some margin pressures.

Quarterly Performance Versus Estimates

The health sciences company reported third-quarter revenue of $699 million, a 2.2% increase compared to the $684 million recorded in the same period last year. This figure came in slightly below the analyst consensus estimate of $714.5 million. On the profitability front, Revvity delivered stronger results with adjusted earnings per share of $1.18, exceeding the $1.16 per share that analysts had projected.

Key financial metrics from the quarter include:

• Revenue: $699 million actual versus $714.5 million estimated
• Adjusted EPS: $1.18 actual versus $1.16 estimated
• GAAP EPS: $0.40, down from $0.77 in Q3 2024
• Adjusted operating margin: 26.1%, down from 28.3% year-over-year

The discrepancy between GAAP and non-GAAP earnings stems from significant adjustments including amortization of intangible assets, restructuring costs, and transformation expenses totaling $0.78 per share.

Market Reaction and Price Action

Following the earnings release, Revvity shares experienced downward pressure in pre-market trading, declining approximately 2.9%. This market response suggests investor concern despite the earnings beat, potentially reflecting disappointment with the revenue performance and compressed margins. The pre-market movement contrasts with the stock's recent positive trajectory, which had seen gains of 12% over the past two weeks and 17.6% over the past month leading into the earnings announcement.

Business Segment Performance

Revvity's operations are divided into two main segments, both showing modest growth but facing profitability challenges:

• Life Sciences Segment:

  • Revenue of $343 million, up 1% year-over-year
  • Organic revenue was flat compared to Q3 2024
  • Adjusted operating profit margin of 29.5%, down from 32.6%

• Diagnostics Segment:

  • Revenue of $356 million, up 3% year-over-year
  • Organic revenue increased 2%
  • Adjusted operating profit margin of 25.1%, down from 27.2%

Updated Guidance and Capital Return

The company provided updated full-year 2025 guidance, adjusting revenue expectations to $2.83-$2.88 billion to account for foreign currency exchange rate fluctuations. This range brackets the analyst consensus estimate of $2.907 billion. Revvity reaffirmed its organic growth guidance of 2% to 4% and raised its adjusted EPS guidance to $4.90-$5.00, compared to the analyst estimate of $4.96 for the full year.

In a significant capital allocation move, Revvity's Board of Directors authorized a new two-year $1 billion share repurchase program, replacing the remainder of the prior authorization announced in October 2024. This substantial buyback program represents approximately 7% of the company's current market capitalization.

Strategic Outlook and Challenges

CEO Prahlad Singh expressed optimism about the company's positioning, stating that "key innovations and strategic partnerships have begun to come to fruition" and that "strong level of execution is positioning the Company for even greater success in 2026 and beyond." However, the results indicate ongoing challenges as the company continues its transformation initiatives, with both segments experiencing margin compression despite modest revenue growth.

The company will host a webcast to discuss these results and business trends on October 27, 2025, providing additional context for investors assessing Revvity's trajectory amid evolving market conditions in the health sciences sector.

For detailed earnings estimates and future projections, view Revvity's comprehensive earnings data.

Disclaimer: This article presents financial information for informational purposes only and does not constitute investment advice, recommendation, or endorsement of any particular security or investment strategy. Investors should conduct their own research and consult with financial advisors before making investment decisions.